Biotech Blog

Biotech Blog Archives: August 2007

next page ·

29 August 2007

Amgen’s patents protect Epogen. Again.

Amgen’s got a record of savvy patenting to protect their blockbusters, and they’ve just done it again.
A U.S. Federal District Court in Boston has ruled that Roche’s pegylated-erythropoietin infringes one of Amgen’s patents.
I’m eager to hear the backstory on this one. Amgen previously prevented Transkaryotic (now owned by Shire) from using a completely different production [...]

continue reading... » 0 Comments

16 August 2007

Drug approvals fall. Who’s to blame?

The FDA approved 38 drugs through July this year, down 31 percent from 55 approvals for the same period last year.
Who’s to blame? According to Friedman, Billings, Ramsey, the FDA. Why? Vioxx.
For details on extra scrutiny being applied by the FDA, see this CNNMoney summary.

continue reading... » 2 Comments

16 August 2007

Carnival of Biotechnology

Welcome to the second August 2007 edition of Carnival of Biotechnology.
International Biotechnology
The Times (UK) has a report on the UK biotech sector, calling for consolidation to overcome a lack of capital.
The Wall Street Journal has an article on Novartis’ lost patent case in India, where a patent on an improved version of Glivec (sold as [...]

continue reading... » 0 Comments

13 August 2007

Journal of Commercial Biotechnology

I’ve recently joined the Journal of Commercial Biotechnology as managing editor. Drop me a line if you would like to make a submission.
The most recent issue, edited by Neil Henderson, has just been published:
Volume 13, Issue 3

When should you fire the founder?
William Bains
Constructing a processual model of communication in new product development from a multiple [...]

continue reading... » 2 Comments

11 August 2007

Call for chapters: Best practices in biotechnology business development

I’m in the final stages of preparing a book on best practices in biotechnology business development, and am looking for 1-2 more chapters. The chapters I’ve received so far are:

Top Five Mistakes
Communicating With Investors and The Media
Securing Intellectual Property From The Inside Out
Aggressive Intellectual Property Strategies
Biotechnology Transfers And Models Facilitate Access To Biotechnological Inventions
Valuation of [...]